Advantage, Data

Genetic testing companies can create private databases to help them interpret the clinical significance of genetic variants, and Duke University's Robert Cook-Deegan and his colleagues argue in the European Journal of Human Genetics that such proprietary collections of data could lead to more expensive tests with less accurate results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.